Abstract Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as diseasemodifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor's function and sequester lymphocytes in lymph nodes. Fingolimod was the first S1P agent approved in the USA in 2010 for relapsing MS after two phase III trials (FREEDOMS and TRANSFORMS) demonstrated potent efficacy, and good safety and tolerability. Postmarketing experience, as well as a third phase III trial (FREEDOMS II), also showed favorable results. More selective S1P receptor agents-ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303-are still in relatively early stages of development, but phase I and II trials showed promising efficacy and safety. However, these observations have yet to be reproduced in phase III clinical trials.
Introduction
Since the introduction of oral disease-modifying therapies (DMTs) over the past several years, the treatment of patients with multiple sclerosis (MS) has changed vastly. Fingolimod was the first approved oral therapy in 2010. It has a unique mechanism of action being a sphingosine 1-phosphate (S1P) receptor modulator. Its clinical efficacy results from modulation of subtype 1 S1P (S1P 1 ) receptors, leading to lymphocyte sequestration in lymph nodes and presumably reduced migration to the central nervous system. However, interactions with other S1P receptor subtypes in other tissues and off-target pharmacologic effects led to interest in more selective S1P receptor agents, which are currently in various stages of development. This review covers the mechanism of action of the S1P receptor modulators as well as their efficacy, safety, and tolerability in MS.
Mechanism of Action of Sphingosine 1-Phosphate (S1P) Receptor Modulators
S1P is an active phospholipid that is the product of the phosphorylation of sphingosine by sphingosine kinase-1 or -2 (SphK1/2) ( Fig. 1) . It regulates diverse cellular responses involved in immunity, heart rate, smooth muscle tone, and endothelial barrier function (Fig. 2) . It is abundant in erythrocytes, brain, spleen, and eyes [1] . S1P receptors have seven transmembrane segments and are coupled to G-proteins, which transduce their actions. There are five subtypes. Subtypes S1P [1] [2] [3] are present ubiquitously, whereas S1P 4 is expressed in lymphoid tissue and S1P 5 in the spleen and oligodendrocytes. B-and T-lymphocytes predominantly express S1P 1 as well as S1P 3 and S1P 4 to a lesser extent. The receptors are important in lymphocyte trafficking, particularly egression from lymph nodes.
In lymph nodes where S1P concentration is typically low, lymphocytes upregulate their S1P receptor expression. When S1P agonistically interacts with its receptor, the bound product is internalized, which leads to activation and transient retention of the T cell in the lymph node. The S1P receptor is then recycled back to the surface. The re-expression of the S1P receptor allows egression from the lymph nodes in response to the efferent lymph-lymph node chemotactic gradient.
Fingolimod
Fingolimod (FTY720, Gilenya Ò , Novartis Pharmaceuticals AG, Basel, Switzerland) is a lipophilic sphingosine-like agent derived from the fungus Isaria sinclairii [2] . It has a structure similar to sphingosine and is phosphorylated by SphK1/2 to become fingolimod-P, an S1P analog. Similar to S1P, fingolimod-P binds to the S1P 1 receptor and is then internalized. However, the S1P receptor is then degraded (Fig. 1) . This degradation prevents cell surface signaling. Hence, S1P receptor modulators such as fingolimod cause indirect antagonism of the S1P receptor's function [3, 4] . The reduction in circulating lymphocytes is dose dependent, with a reduction of 20-30 % within the first week of treatment and reaching a maximal response of approximately 70 % [4, 5] . The intended action of fingolimod is through binding of the S1P 1 receptor on lymphocyte surfaces. However, its nonselective modulation of S1P 3 , S1P 4 , and S1P 5 may lead to unwanted adverse effects, which are discussed further below [6, 7] . The elimination half-life of fingolimod is 6-9 days, with about 81 % of the dose excreted as inactive metabolites in urine [8] .
Efficacy
In the FREEDOMS phase III trial, fingolimod was shown to decrease annualized relapse rate (ARR) by 54 and 60 %, Fig. 1 Mechanism of action of fingolimod. Binding to S1P 1 leads to receptor internalization and degradation, resulting in functional antagonism. S1P sphingosine 1-phosphate, SphK1/2 sphingosine kinase-1 or -2 respectively, for 0.5 and 1.25-mg doses compared with placebo [5] . Results on time to first relapse and confirmed Expanded Disability Status Scale (EDSS) worsening also favored fingolimod. Fingolimod also significantly reduced gadolinium-enhancing (GdE) magnetic resonance imaging (MRI) lesions (*90 %) and new or enlarging T2 lesions (*50 %) at 24 months. Moreover, there was significant preservation of brain volume in participants receiving 0.5 mg than in those receiving placebo (-0.84 vs. -1.31 %) from baseline to 24 months. These results were largely confirmed in a second placebo-controlled phase III trial, FREEDOMS II [9] .
In the TRANSFORMS trial, both doses of fingolimod (0.5 and 1.25 mg) were demonstrated to be superior to interferon (IFN)-b-1a in decreasing the ARR by 52 and 38 %, respectively [10] . The proportion of relapse-free participants and time to confirmed relapse were greater in both fingolimod groups. On MRI, the numbers of GdE lesions and new or enlarging T2 lesions were significantly lower in the fingolimod groups than in the IFNb-1a groups. Brain volume reductions were significantly less with both fingolimod doses than with IFNb-1a. Given the equivalent efficacy of the two doses, fingolimod 0.5 mg was approved under the brand name Gilenya by the US FDA in 2010 as the first oral agent. In 2011, it was approved in Canada, Europe, and the rest of the world. In Japan, fingolimod is marketed as Imusera Ò and is developed by both Mitsubishi Tanabe and Novartis.
Safety, Tolerability, and Adverse Effects
Several adverse effects were noted in the three phase III trials (FREEDOMS, FREEDOMS II and TRANSFORMS), many of which were attributed to fingolimod's nonselective modulation of the S1P receptors. Common adverse effects were first-dose bradycardia or atrioventricular block, macular edema, headache, hypertension, cough, dyspnea, back pain, headache, influenza, and diarrhea.
Combined analysis from FREEDOMS and TRANS-FORMS showed a mean decrease in heart rate of 8 beats per minute, reaching a nadir 4-5 h post first dose. The incidence of first-degree atrioventricular block was 4.7 %; Mobitz type 1 second-degree atrioventricular block occurred in 0.2 % of participants, and symptomatic bradycardia in 0.5 % [11] . As a result, upon approval of fingolimod by the FDA, a strict monitoring protocol for the first 6 h post first dose administration was instituted. Discontinuation of fingolimod for more than 2 weeks requires repeat first-dose monitoring due to the recurrence of bradycardia. The mechanism behind fingolimod's effect on heart rhythm is via transient agonistic effects on S1P 1 receptors in atrial myocytes, followed by desensitization due to receptor down-modulation [12] . This is different from S1P receptor modulation in rodent atrial myocytes, which is via S1P 3 [13, 14] . Evidence to support this distinction is in the noted cardiac effects of selective S1P 1 agents, as discussed later [15] . Fig. 2 Interaction of fingolimod and selective S1P receptor drugs with S1P receptor subtypes. CV cardiovascular, S1P sphingosine 1-phosphate, SphK1/2 sphingosine kinase-1 or -2, T H 17 T-helper cell 17 Several other adverse effects of fingolimod were noted, for which the underlying mechanism is less clear and may be due to off-target effects via other S1P receptor subtypes. The incidence of macular edema from the pivotal trials was 0.3 %, leading to the requirement for an ophthalmologic exam evaluating for macular edema prior to treatment and 3 months post initiation [16, 17] . The overall incidence of infections in the trials was similar in the fingolimod-treated participants and those treated with placebo (FREEDOMS, FREEDOMS II) and IFNb-1a (TRANSFORMS) [5, 9, 10] . However, herpes zoster, lower respiratory tract infections, and influenza had a somewhat higher incidence in participants receiving fingolimod. In the clinical trials, two cases of fatal varicella zoster were reported [18] . The first patient received fingolimod 1.25 mg for 10 months and developed primary disseminated zoster [10] . The second case was in a post-marketing observational study. The patient previously received natalizumab, had positive varicella zoster titers, and developed reactivation within 6 months of administration of fingolimod 0.5 mg. Recently, a case of herpes simplex encephalitis in a patient receiving fingolimod was reported [19] . These cases highlight the potential increased risk of herpes infections in patients receiving fingolimod. Asymptomatic threefold elevation of liver transaminases was reported in about 10 % of fingolimod-treated participants in the combined analysis of FREEDOMS and TRANSFORMS. However, the incidence of transaminase elevations was lower in the FREEDOMS II trial, and abnormalities normalized upon discontinuation of fingolimod without liver failure [9] . A few cases of lymphoma have been reported in animal trials and post-marketing data, but the relationship to fingolimod is uncertain [20] .
Similar to other DMTs, fingolimod is pregnancy category C, as preclinical studies have shown a risk of fetal toxicity [21] . Pooled from nine phase II, III, and IV trials, 66 pregnancies with in utero exposure to fingolimod were reported. Of those, 24 underwent elective abortion, nine experienced spontaneous abortion, four remained ongoing, and one was unknown. Two birth defects were seen: unilateral bowing of the tibia, and acrania. Three of the elective abortions were due to developmental defects, including a case of tetralogy of Fallot. The number of cases remains too small to draw proper conclusions. However, it is important to counsel patients on fingolimod for adequate contraception and allow a washout period of at least 2 months prior to conception.
To date, there are 11 known cases of progressive multifocal leukoencephalopathy (PML) in patients receiving fingolimod who have also had prior exposure to natalizumab [22] . A case of PML on fingolimod was reported in 2012, but further investigation revealed the patient likely had neuromyelitis optica. In February 2015, Novartis reported a case of PML in a patient with MS who had been treated with fingolimod for 4 years without prior exposure to natalizumab [23] . A routine MRI scan showed two large non-enhancing T2 lesions in the cerebellum and temporal regions, one of which had high signal intensity on diffusion weighted imaging and apparent diffusion coefficient map. The diagnosis of PML was confirmed via positive John Cunningham virus (JCV) serology in blood and cerebrospinal fluid polymerase chain reaction. The patient had no known history of medications or comorbidities associated with PML, and absolute lymphocyte counts were 240-890 cells/lL. Despite this case report, the estimated risk of PML remains low based on the observed rate in more than 114,000 patients treated with fingolimod in clinical trials and clinical practice.
Fingolimod Administration and Monitoring
Fingolimod is approved by the FDA in the USA as first-line therapy in relapsing forms of MS [8] . In Europe, it is approved for highly active MS in patients for whom at least one other DMT had failed or with disease that is severe and rapidly getting worse. Fingolimod was not studied in the pediatric population nor is it approved for use in that age. A clinical trial assessing the safety and efficacy of fingolimod in pediatric patients with MS is underway (NCT01892722). At the Cleveland Clinic Mellen Center, fingolimod is offered as a first-line treatment to patients who are disinclined to injection therapy or those with highly active disease who are not appropriate candidates for natalizumab, i.e. JCV seropositive [24] .
Prior to initiation of therapy, a complete blood count (CBC), alanine aminotransferase (ALT), aspartate transaminase (AST), pregnancy test, and varicella zoster immunoglobulin (Ig)-G titer are checked (confirming exposure to chickenpox or shingles). Patients undergo ophthalmologic examination or optical coherence tomography (OCT) to assess for macular edema prior to treatment initiation. OCT of the macula can detect trace edema that might not be evident on dilated fundoscopy [25] . Baseline electrocardiogram (ECG) is carried out with consideration for a cardiology referral if the ECG is abnormal or there is a history of heart disease. Pulmonary referral is considered if there is a history of severe asthma or chronic obstructive pulmonary disease. While the patient is receiving therapy, ALT and AST are assessed at 3 and 6 months, ophthalmologic examination or OCT is repeated at 3-4 months, and pulmonary evaluation is considered if the patient develops dyspnea or persistent cough.
Long-Term Experience with Fingolimod
The results of the extension phase of the FREEDOMS trial were presented at the 2012 American Academy of Neurology (AAN) meeting in New Orleans and have been published recently [26, 27] . This extension phase included participants receiving treatment for up to 4 years. Participants receiving placebo were randomized to fingolimod 0.5 or 1.25 mg; those already receiving fingolimod (0.5 or 1.25 mg) remained on the prior dose. Of the 81 % who completed the 2-year core trial, 84 % completed the extension phase (about two-thirds of the original cohort). The ARR decreased from 0.4 to 0.2 in those who switched from placebo to fingolimod 0.5 mg. For participants who received continuous fingolimod 0.5 mg throughout the trial, the overall reduction in relapse rate was 48 % compared with placebo. Of participants who were maintained on 0.5 mg, 59 % remained relapse-free compared with 37 % of those who were switched. Similar improvements were noted on MRI measures (mean number of new or enlarging T2 and mean number of GdE). The risk of 6-month confirmed disability worsening was reduced in the continuous fingolimod 0.5-mg group by 31 % compared with those switched.
LONGTERMS is an ongoing, multicenter, open-label, single-arm, long-term safety and tolerability study [28] . It includes participants from the phase II study, FREEDOMS, FREEDOMS II, TRANSFORMS, as well as some participants from phase IIIb studies (e.g. FIRST, FIRST-LATAM, TOFINGO, and VERIFY) who were receiving the approved 0.5-mg dose. The latest analysis includes annual assessments from 2010 to August 2013, although the study will continue until 2016. In the analysis, two cohorts were analyzed; those from the 'core' phase III studies [core cohort (CC)] who did not continue into the extension phase of their trial (n = 1212) and a 'long-term' cohort (LC), which includes the CC in addition to participants from the aforementioned trials (n = 1655). LC also includes participants who were receiving placebo or IFNb1a and were switched to fingolimod. The median duration of exposure to fingolimod was 3.7 years (up to 7.4 years) in the LC and 1.6 years (up to 2.4 years) in the CC. The incidence rate of adverse events was lower in the LC than in the CC, and included infections, cardiac events, skin cancer and other malignant neoplasms, thromboembolic events, hypertension, respiratory conditions, and macular edema. This decrease in incidence may be related to the loss of patients from the core studies (possibly due to adverse events). Importantly, no new adverse events were noted. The incidence rate of leucopenia and lymphopenia was greater in the LC, but this did not appear to be associated with an increased risk of infection.
Hersh et al. reported on 306 patients treated at a large academic center with 12-month follow-up after starting fingolimod [29] . About 72.6 % were switched directly from another DMT, most due to intolerance, risk, convenience, or breakthrough disease. Of those, 11.6 % were switched from natalizumab. Most patients tolerated fingolimod well, but about 25 % discontinued treatment, most often due to adverse effects (13 %) or breakthrough disease (7 %). There rates was comparable to the discontinuation rates in FREEDOMS (19 %) and FREEDOMS II (32 %). The range of adverse effects noted in this observational study was similar to that seen in the clinical trials.
Use of Fingolimod Following Natalizumab
Fingolimod's relatively strong efficacy in its phase III trials has led to its use as a second-line agent in patients with highly active disease who have antibodies to the JCV. It has been a common agent to switch to in patients receiving natalizumab and who are at increased risk for developing PML due to JCV seropositivity.
Rebound disease activity post natalizumab discontinuation is a potential complication. However, the ideal washout period between natalizumab and the next agent is uncertain [30, 31] . A French prospective study evaluated 333 patients switching from natalizumab to fingolimod with a mean inter-drug washout duration of 17 weeks [32] . During that period, 55 % did not receive treatment and 39 % received methylprednisolone. The risk of relapse was higher in patients who had a longer washout duration (20 % for \3 months and 59 % for [6 months); although no difference was observed in the risk of relapse with the use of methylprednisolone. Jokubaitis et al. [33] retrospectively reviewed 536 patients receiving fingolimod from the MSBase Registry. Of those, 89 patients were switched from natalizumab with a median inter-drug duration of 11.3 weeks. However, no significant increase was observed in relapses in the first 6 months receiving fingolimod, as 85 % of patients remained relapse free. Despite the slight increase in relapse rate after the switch, the rate remained lower than pre-natalizumab, and hence no evidence of rebound activity was seen. TOFINGO is an ongoing phase IV trial that assesses immune function and MRI activity in patients switching from natalizumab to fingolimod (ClinicalTrials.gov identifier: NCT02325440). Preliminary MRI results were presented at the 2013 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen, Denmark [34] . A total of 142 participants were randomized to 8, 12, or 16 weeks of washout between the two drugs, and MRI brain was performed at baseline and 8, 12, 16, 20, and 24 weeks. The mean number of active MRI lesions was significantly higher on the 16-week MRI (8.2 lesions) than on the 8-and 12-week images (2.1 and 1.7 lesions, respectively). On the 24-week MRI, more participants were free of GdE with the shorter washout (75 % for 8 weeks vs. 47.5 % for 16 weeks). Thus, several studies have shown that when switching from natalizumab to fingolimod, the risk of relapse increases with longer washout period [35, 36] . In most patients, fingolimod maintains good control of relapse activity.
Fingolimod in Progressive Multiple Sclerosis (MS)
INFORMS is a recently completed randomized, doubleblind, placebo-controlled phase III trial of fingolimod in patients with primary progressive MS (ClinicalTrials.gov identifier: NCT00731692) [37] . In the trial, 970 patients were randomized to fingolimod 0.5 mg versus placebo. The primary endpoint was reduction in risk of 3-month confirmed disability worsening based on a composite measure combining EDSS, 9-hole peg test, and 25-foot walk. The trial was completed in September 2014 and has not yet been published. Preliminary results from the AAN 2015 annual meeting revealed no benefit on either the composite endpoint or EDSS [38] . Although suppression of MRI inflammatory activity was noted, it did not improve the primary outcome or reduce brain volume loss.
Selective S1P Receptor Drugs
The efficacy of fingolimod has led to an interest in developing small-molecule S1P receptor modulators with shorter half-lives, similar broad tissue distribution, preserved efficacy, more S1P receptor selectivity, and hopefully decreased adverse effects. Currently, at least six potential S1P receptor drugs are in various stages of testing. Selectivity for S1P 1 receptors theoretically is favored to preserve efficacy and minimize adverse events related to other S1P receptor subtypes [14] .
Ponesimod
Ponesimod (ACT-128800, Actelion Pharmaceuticals, Allschwil, Switzerland) is a selective S1P 1 receptor modulator that was investigated in a 24-week, phase IIb, double-blinded, placebo-controlled trial that aimed to evaluate the efficacy, safety, and tolerability of three doses (10, 20 , and 40 mg) in relapsing-remitting MS (RRMS) [39] . The 20 and 40-mg arms included a titration schedule, while the 10-mg and placebo groups included mock titrations. The primary endpoint was cumulative number of new GdE lesions from weeks 12 to 24. Secondary endpoints included ARR, time to first confirmed relapse over 24 weeks, cumulative number of new or enlarging T2 lesions at 12-24 weeks, combined unique active lesions (CUALsGdE and new or enlarging T2 lesions), and change in brain volume from baseline.
A total of 464 participants were randomized into four study arms, with about 79-90 % of participants completing each arm. A significant reduction was observed in new GdE lesions from week 12 to 24 with all three doses of ponesimod compared with placebo but more so in the 20 and 40-mg groups (83 and 77 % reduction, respectively). Benefits on ARR reduction and time to first confirmed relapse were only significant in the 40-mg arm at 52 % (p = 0.0363) and 58 % (p = 0.0189), respectively. The 20 and 40-mg doses showed significant reduction in CUAL but not in new or enlarging T2 lesions; and all three doses showed preservation in brain volume at 24 weeks compared with placebo. Although there appears to be a dose-dependent effect, it does not continue above the 20-mg dose.
The 10 and 20-mg doses appeared to be well tolerated compared with the 40-mg dose. Only 2 % of participants receiving ponesimod experienced bradycardia (decrease of about 15 beats per minute); and 1.2 and 0.9 % of the respective cohorts had first-and second-degree heart block, all of which occurred only on the first day of the 10-mg dose, and within 2-3 h of administration. Other adverse effects reported in the ponesimod cohorts include anxiety, dizziness, dyspnea, increased ALT (more than three times the upper limit of normal), influenza, insomnia, and peripheral edema. Dyspnea and peripheral edema were dose dependent, and seven participants prematurely discontinued due to dyspnea (six in the 40-mg group). The decrease in forced expiratory volume in 1 s (FEV 1 ) was seen in 0.6-10 % of participants receiving ponesimod, and returned to baseline within 1 week of discontinuation. Macular edema was seen in four participants, three of whom were in the 20-mg cohort and one was receiving placebo. The average reduction in lymphocyte count up to week 24 was 50-69 % for ponesimod as opposed to 3 % for placebo. Most of the reduction occurred by day 8 and recovered within the first week of discontinuation. A 5-year extension study is currently ongoing (ClinicalTrials.gov Identifier: NCT01093326).
Siponimod
Siponimod (BAF312), currently under development by Novartis Pharma AG, binds to both S1P 1 and S1P 5. The phase II BOLD trial was a double-blind randomized trial completed in October 2010 comparing multiple doses of BAF312 (0.25, 0.5, 1.25, 2, and 10 mg) against placebo [40] . The 6-month study had a primary endpoint of CUAL (new GdE and new or enlarging T2 lesions without double counting) over the first 3 months. Secondary measures included total monthly new GdE lesions, total monthly new or enlarging T2 lesions, ARR, and proportion of participants who were relapse free. Efficacy of the 2 and 10-mg doses was about the same, with a reduction in CUAL by 72 and 82 %, respectively, but was submaximal for the 0.5-mg dose. The ARR was significantly lower in the 2 and 10-mg doses (0.2 and 0.3, respectively) versus placebo (0.58). However, the ARR reduction was statistically significant for the 2-mg dose only.
Of the higher dose (2 and 10 mg) cohorts, 5 % experienced second-degree atrioventricular block and 17 % had bradycardia. One participant with a history of coronary artery disease receiving the 1.25-mg dose died 27 days after discontinuing the medication. This was suspected to be a combination effect from the study drug as well as underlying coronary artery disease. Another participant receiving the 10-mg dose had a nonfatal myocardial infarction 45 days post discontinuation. This was attributed to siponimod. Elevation in ALT (more than three times the upper limit of normal) was more frequent in the higher doses. The magnitude of reduction in lymphocyte count at day 7 plateaued with the 2-mg dose. Given the efficacy and safety data in this phase II trial, the 2-mg dose appeared to be the most appropriate dose for future trials, especially if titrated to mitigate its cardiac effects.
The phase III EXPAND trial is an ongoing placebocontrolled randomized trial in secondary progressive MS (SPMS) patients that began in December 2012 (ClinicalTrials.gov identifier: NCT01665144). The primary outcome measure is delay in time to confirmed disability worsening measured by EDSS, with secondary measures including timed 25-foot walk, T2 lesion volume, ARR, time to first relapse, response rate on the 12-item MS walking scale (MSWS-12), number of patients with adverse events, and number of patients with abnormal laboratory tests.
Ozanimod
Ozanimod (RPC1063) is a selective oral S1P 1 modulator that is in clinical development by Receptos, Inc. (San Diego, CA, USA). It was previously tested as single and multiple doses in healthy volunteers [41] .
RADIANCE is a phase II/III trial of ozanimod in adult patients with relapsing MS. The results of the phase II portion were presented at the 2014 Americas Committee for Treatment and Research in MS (ACTRIMS)/ECTRIMS meeting in Boston, USA [28] . In this 24-week placebocontrolled trial, 258 participants were randomized to receive ozanimod 0.5 or 1 mg or placebo. The primary efficacy endpoint was the cumulative number of GdE lesions on monthly scans from weeks 12 to 24. Secondary measures included the cumulative number of new or enlarging T2 lesions from weeks 12 to 24, the number of GdE lesions at week 24, ARR, and the safety and tolerability of ozanimod.
Overall, the study had a high rate of completion ([96 %), similar across the treatment groups. The study met its primary endpoint with an 86 % reduction in cumulative number of GdE lesions from weeks 12 to 24 for both doses compared with placebo. Secondary endpoints favored ozanimod, with a 91 and 94 % reduction in the total number of GdE lesions at week 24 (0.5 and 1-mg doses, respectively). The cumulative number of new or enlarging T2 lesions from weeks 12 to 24 was reduced by 84 and 91 %. ARR was reduced by 31 and 53 %, respectively, approaching significance for the higher dose.
In total, three serious adverse effects unrelated to therapy were reported with the 0.5-mg dose: optic neuritis, somatoform autonomic dysfunction, and uterine cervical squamous metaplasia. Other adverse reactions included nasopharyngitis, headache, and urinary tract infection (no significant difference in incidence among the treatment groups). Rare elevation in ALT more than three times the upper limit of normal was noted in both ozanimod groups (1-2 %). The first-dose effects on cardiac conduction were minimal. Second-degree atrioventricular block was seen in \3 % of both ozanimod and placebo groups, and 74 % of the ozanimod cohort maintained a heart rate above 60 beats per minute in the first 24 h.
Based on the preliminary results of the phase II portion, the phase III portion of the RADIANCE study, comparing ozanimod against intramuscular IFNb-1a, was initiated. A second phase III trial, SUNBEAM (ClinicalTrials.gov identifier: NCT02294058), is in start-up.
Ceralifimod
Ceralifimod (ONO-4641, Ono Pharmaceutical Co. Ltd, Osaka, Japan) is an oral, selective S1P 1 and S1P 5 [42] [43] [44] . At this time, whether further development of this drug will proceed is unclear.
GSK2018682
GSK2018682 is a selective S1P 1 receptor modulator with some activity at S1P 5 that is currently under development by GlaxoSmithKline (London, UK). Three phase I studies evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2018682 in humans were completed in 2010 and 2011 [45] . GSK2018682 has been reasonably tolerated following single oral doses of 0.6-24 mg (ClinicalTrials.gov Identifier: NCT01466322). However, the GlaxoSmithKline Product Development Pipeline from March 2015 does not list GSK2018682. Thus, it does not seem as though the drug will be moving forward.
MT-1303
MT-1303 is a selective S1P receptor (unknown subtype) modulator in development by Mitsubishi Tanabe Pharma (Osaka, Japan). The drug was tested in a phase II dose-finding trial completed in October 2014 (ClinicalTrials.gov Identifier: NCT01742052). An extension of the phase II study is planned (ClinicalTrials.gov Identifier: NCT01890655).
Selective Versus Nonselective S1P Agents
Based on the phase II data for the selective S1P receptor modulators, the effects on lymphocyte reduction, development of GdE lesions, and ARR are generally similar to those of fingolimod (Table 1) . However, the selective S1P agents appear to have the advantage of a shorter half-life and more rapid lymphocyte recovery post discontinuation [4, 15, 46] . These differences would allow flexibility in retreatment with other agents, aid in washout to treat potential opportunistic infections, and address other treatment-related complications or eliminate the drug in unplanned pregnancy. However, despite the selectivity of the new S1P receptor modulators, some side effects such as first-dose bradycardia and conduction block were still seen in some of the agents. This is because human S1P receptors mediating these effects in cardiac myocytes are S1P 1 [13, 14] . Gradual up-titration of the dose may abrogate first dose cardiac effects for some agents. In some instances, as in the case of ponesimod, respiratory adverse effects were also noted [39] .
Conclusion
The development of S1P receptor modulators has opened the door for a novel mechanism of reducing inflammatory lesion activity in MS patients. These agents are effective and have good safety and tolerability as evidenced by fingolimod's post-marketing record. The newer selective agents also seem to show promise in maintaining that efficacy while adding the potential advantages of improved pharmacodynamics and tolerability. However, these observations have yet to be reproduced in phase III clinical trials.
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